{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T16:44:25Z","timestamp":1700066665078},"reference-count":72,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,3,13]],"date-time":"2007-03-13T00:00:00Z","timestamp":1173744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2007,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The acquired clonal disorder Polycythaemia Vera leads to increased erythropoiesis, myelopoiesis and megakaryopoeisis. These anomalies result in an increased incidence of thromboembolic events, transformation to acute leukaemia and myelofibrosis. Treatments which aim to reduce the event rate may increase anaemia but may also affect the rate of complications. This paper reviews the evidence for the treatments which have been used in the management of the disorders over a 50 plus year period. Assessment of this evidence and its limitations form the basis for the current suggested management plans. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.809","type":"journal-article","created":{"date-parts":[[2007,3,13]],"date-time":"2007-03-13T09:34:26Z","timestamp":1173778466000},"page":"58-65","source":"Crossref","is-referenced-by-count":8,"title":["A review of the therapeutic agents used in the management of polycythaemia vera"],"prefix":"10.1002","volume":"25","author":[{"given":"Mary Frances","family":"McMullin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,3,13]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)90179-9"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92098-6"},{"key":"e_1_2_1_4_2","first-page":"166","volume-title":"Treatment of polycythaemia vera, a summary of clinical trends conducted by the polycythaemia vera study group","author":"Berk PD","year":"1995"},{"issue":"3","key":"e_1_2_1_5_2","first-page":"172","article-title":"Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera","volume":"23","author":"Tartaglia AP","year":"1986","journal-title":"Semin. Hematol"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb03289.x"},{"issue":"1","key":"e_1_2_1_7_2","first-page":"6","article-title":"The very long\u2010term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981","volume":"34","author":"Najean Y","year":"1997","journal-title":"Semin. Hematol"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.7.2319"},{"issue":"9","key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years","volume":"90","author":"Najean Y","year":"1997","journal-title":"Blood"},{"issue":"5","key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1182\/blood.V92.5.1837","article-title":"Leukemic transformation in polycythemia Vera. MPD(UK) Study Group","volume":"92","author":"Pearson TC","year":"1998","journal-title":"Blood"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1981.150"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.362682.x"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035572"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830170402"},{"issue":"3","key":"e_1_2_1_15_2","first-page":"167","article-title":"Long\u2010term management of polycythemia vera with hydroxyurea: a progress report","volume":"23","author":"Kaplan ME","year":"1986","journal-title":"Semin. Hematol"},{"issue":"1","key":"e_1_2_1_16_2","first-page":"17","article-title":"From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera","volume":"34","author":"Fruchtman SM","year":"1997","journal-title":"Semin. Hematol"},{"issue":"1","key":"e_1_2_1_17_2","first-page":"24","article-title":"Management of polycythemia vera with hydroxyurea","volume":"34","author":"Tatarsky I","year":"1997","journal-title":"Semin. Hematol"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321704"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.03849.x"},{"issue":"11","key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood.V95.11.3589","article-title":"Acquired DNA mutations associated with in vivo hydroxyurea exposure","volume":"95","author":"Hanft VN","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.2.616"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(64)90330-7"},{"key":"e_1_2_1_24_2","first-page":"560","article-title":"Contrasting incidence of acute monocytic and granulocytic leukemias in p32 treated patients with polycythemia vera and chronic lymphocytic leukemia","volume":"64","author":"Osgood EE","year":"1964","journal-title":"J Lab Clin Med"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5545.146"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(65)90812-3"},{"key":"e_1_2_1_27_2","first-page":"833","article-title":"A\u20108103","volume":"190","author":"Monto RW","year":"1964","journal-title":"In Polycythaemia"},{"issue":"5","key":"e_1_2_1_28_2","first-page":"491","article-title":"Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea","volume":"35","author":"Boivin P","year":"1993","journal-title":"Nouv. Rev. Fr. Hematol"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb08324.x"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01737425"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830430419"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb03306.x"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.6.1232"},{"issue":"1","key":"e_1_2_1_34_2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood.V36.1.70.70","article-title":"Melphalan therapy of polycythemia vera","volume":"36","author":"Logue GL","year":"1970","journal-title":"Blood"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830280113"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820901)50:5<836::AID-CNCR2820500505>3.0.CO;2-W"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950115)75:2<471::AID-CNCR2820750210>3.0.CO;2-B"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1958.03000140042011"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1985.tb02880.x"},{"issue":"10","key":"e_1_2_1_40_2","first-page":"1130","article-title":"Anagrelide\u2010induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies","volume":"88","author":"Thiele J","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90017-6"},{"issue":"1","key":"e_1_2_1_42_2","first-page":"51","article-title":"Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders","volume":"34","author":"Petitt RM","year":"1997","journal-title":"Semin. Hematol"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0676"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402938"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3917"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05535.x"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198703000-00012"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1988.tb00212.x"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1994.tb01303.x"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199605)52:1<42::AID-AJH7>3.0.CO;2-6"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10375"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1961.tb00326.x"},{"key":"e_1_2_1_53_2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood.V32.4.536.536","article-title":"A study of hematological complications occuring in patients with polycythaemia vera treated with 32P","volume":"32","author":"Tubiana M","year":"1968","journal-title":"Blood"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-70-4-763"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01468756"},{"issue":"3","key":"e_1_2_1_56_2","first-page":"461","article-title":"Haematological complications in polycythaemia vera and thrombocythaemia patients treated with radiophosphorus (32P)","volume":"117","author":"Randi ML","year":"1990","journal-title":"Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1995.tb01621.x"},{"key":"e_1_2_1_58_2","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1182\/blood.V59.5.890.890","article-title":"Pipobroman Therapy of Polycythaemia Vera","volume":"59","author":"Najman A","year":"1982","journal-title":"Blood"},{"issue":"6","key":"e_1_2_1_59_2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.1984.2.6.558","article-title":"Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia","volume":"2","author":"Brusamolino E","year":"1984","journal-title":"J. Clin. Oncol"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401045"},{"issue":"10","key":"e_1_2_1_61_2","first-page":"1011","article-title":"Efficacy of pipobroman in the treatment of polycythemia vera: long\u2010term results in 163 patients","volume":"85","author":"Passamonti F","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200250"},{"issue":"12","key":"e_1_2_1_63_2","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/blood.V77.12.2790.2790","article-title":"Recombinant interferon alpha in the treatment of polycythemia vera","volume":"77","author":"Cacciola E","year":"1991","journal-title":"Blood"},{"issue":"1","key":"e_1_2_1_64_2","first-page":"75","article-title":"Alpha\u2010interferon in polycythemia vera and essential thrombocythemia","volume":"76","author":"Turri D","year":"1991","journal-title":"Haematologica"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830440303"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1994.tb00191.x"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.00303.x"},{"issue":"1","key":"e_1_2_1_68_2","first-page":"40","article-title":"Interferon alfa: effects of long\u2010term treatment for polycythemia vera","volume":"34","author":"Silver RT","year":"1997","journal-title":"Semin.Hematol"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1998.tb01039.x"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1159\/000040817"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-199804000-00004"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1999.tb01110.x"},{"key":"e_1_2_1_73_2","doi-asserted-by":"crossref","unstructured":"LawrenceJH.Nuclear Physics and therapy: Preliminary report on a new method for the treatment of Lukemia and Polycythemia Radiology1940;35(1)51\u201360.","DOI":"10.1148\/35.1.51"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.809","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T16:04:16Z","timestamp":1700064256000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,13]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["10.1002\/hon.809"],"URL":"https:\/\/doi.org\/10.1002\/hon.809","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,13]]}}}